Latest news
Radioligand Therapy Is Building Its Evidence Base. Now Build the Infrastructure.
Phase III COMPETE data published in The Lancet show ¹⁷⁷Lu-edotreotide improved progression-free survival and response rate versus everolimus in advanced GEP-NETs. The policy question is no longer whether radioligand therapy is serious. It is whether systems are.
Pharmacists are becoming the front door for cardiometabolic care. Policy is still treating them like the back office
Dementia prevention has a cardiometabolic blind spot
BRCA Care Cannot Start at Diagnosis
The Money Is Moving Into Cancer Screening. The Evidence Still Has to Catch Up.
Huntington’s Needs More Than a Better Curve
Duchenne’s Accelerated Approval Faces Its Test
The Screwworm Border Did Not Hold. Now Mexico and the U.S. Are Betting on Flies.
New nicotine products could become the next major cardiovascular policy failure
Childhood obesity is the next cardiometabolic crisis already unfolding
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.